{"name":"BioLite, Inc.","slug":"biolite-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"BLEX 404 Oral Liquid","genericName":"BLEX 404 Oral Liquid","slug":"blex-404-oral-liquid","indication":"Type 2 diabetes","status":"phase_2"}]}],"pipeline":[{"name":"BLEX 404 Oral Liquid","genericName":"BLEX 404 Oral Liquid","slug":"blex-404-oral-liquid","phase":"phase_2","mechanism":"BLEX 404 Oral Liquid is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQTFBSQXBOMW5PeVhuOHVaLUYzeUswZ3B1QXFwNEdWU28xc0ktSndQWnE3aFZKa2trTDBGMzFLVGdfdndnOGJHSWJXUldEeE5Rbk04Q0taY0hjY1pzaGFCS041Y3J3elBLa0RNeTgzNV9KSFlvNTRLUUcyeDdyVFJDVVpuTDNod3VqdHJDN0JQdUY?oc=5","date":"2026-04-06","type":"pipeline","source":"openPR.com","summary":"Triple Negative Breast Cancer Pipeline 2026: MOA, ROA, - openPR.com","headline":"Triple Negative Breast Cancer Pipeline 2026: MOA, ROA,","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxOZFFXbjY5X19SVW9xSlRDdjdlUkgzYnRNbnFFRzU5WjBwUXpyS2xYRm5Sd2sxWndTZ3RpOHFiNEJjbU1CXzg1M3hwSkN5TW1tY05TZG5BMmtGNmZNS1F5WGRxR3F5MzhqSnRzWndvaS0zMGgxQWdfU2VwU1V2ckZxYVVEOGxDRlMzTEVsZm5yU045QWhLWURlTXdRcFhXSXZTb0h0WjVBMklWTTNLVG5hdm04MG1hWUJXUEdUSFlnZHNPT2VuNlFkNXEtVGNXc1FPang4Q09JOVVKMjNTYjB2ZHd3QlVlUC13ZkR2RG5OV0llZ3hicUg5SjdPc1lieXE4eUR0X2lnRTY0SUlDTzRPV1dpQU1tMWRDYjZGTGh1enZpS1RJa2w1SWRtbWF4dw?oc=5","date":"2025-06-26","type":"trial","source":"globenewswire.com","summary":"Autism Spectrum Disorder Clinical Trial Analysis: Key - globenewswire.com","headline":"Autism Spectrum Disorder Clinical Trial Analysis: Key","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgJBVV95cUxOd0p6eTU0bHJFbDFqSV84R1BRcm01TF8yVlplZnE3VVE2dTJKOHR5ZFdOLWlKT2ZnbHlfdlBMNm9lVXVmMnBpejd2ajRxeEhhQk1CRHNPZE5GQ1VaYUJmanNuME5idFhJaW9BbnhmR0haTFRjWXZ3MlpKQ25EVnNHMVAyc0VWT2VubnN1SnpLRXliUGZLNFpfZGU1MEt5akluVTVZOTdpTHZXRjVobnVicVU3TGNIeTFoa0Z2azBYM0txclRDZVhDOFNkNTEtcE9ZREVFVW5xZ1JhV3lTVnZxRXNsQ3huZi15ZUEyS1dHcnIzZWlOX0hIZ0hCMGRLdWl6U01PcmZZcG1FLWhneWVGQzdtSmdlVk1PLUVrRlcxc1BRT2dmRFFHekN6TGlXYlZ3VzBRd3Vn?oc=5","date":"2025-01-22","type":"trial","source":"globenewswire.com","summary":"5-HT2 Agonist Clinical Trial Pipeline Appears Robust With - globenewswire.com","headline":"5-HT2 Agonist Clinical Trial Pipeline Appears Robust With","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}